Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

HMGB1 inhibitor SB17170

An orally bioavailable prodrug of SB1703, a small molecule inhibitor of high mobility group protein B1 (HMGB1), with potential immunomodulating and antineoplastic activities. Upon oral administration, SB17170 is converted to its active metabolite SB1703. SB1703 targets, binds to, and inhibits the activity of HMGB1. This inhibits HMGB1-mediated activation of immune-suppressive myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME), thereby halting MDSC-mediated immunosuppression and enhancing T-cell-mediated anti-tumor immune responses. HMGB1, a damage-associated molecular pattern (DAMP) that acts as an immunomodulator, plays an important role in tumor cell proliferation, angiogenesis and metastasis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:SB1703 prodrug SB17170
Code name:SB 17170
SB-17170
SB17170
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search